USPTO Examiner NOBLE MARCIA STEPHENS - Art Unit 1632

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17125449FRATAXIN EXPRESSION CONSTRUCTSDecember 2020January 2024Allow3720NoNo
17253518METHOD OF DIFFERENTIATING PRIMORDIAL GERM CELL INTO PRIMORDIAL FOLLICLE IN VITRODecember 2020March 2024Allow3920YesNo
17118981HUMANIZED HEART MUSCLEDecember 2020February 2025Abandon5021NoNo
17118064NON-MEIOTIC ALLELE INTROGRESSIONDecember 2020January 2024Abandon3811NoNo
16952807HUMANIZED SKELETAL MUSCLENovember 2020May 2024Allow4220NoNo
17091203Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain InjuriesNovember 2020August 2024Abandon4521NoNo
17086072METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTUREOctober 2020June 2023Allow3110YesNo
17065541Method For Differentiating Pluripotent Stem Cells Into Desired Cell TypeOctober 2020September 2023Allow3610NoNo
17039006CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCSSeptember 2020May 2025Allow5641YesNo
17040818Gene Editing for Autosomal Dominant DiseasesSeptember 2020May 2025Abandon5511NoNo
16937370MODIFIED NK-92 haNK003 CELLS FOR THE CLINICJuly 2020April 2023Allow3310YesNo
16925518IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLSJuly 2020November 2023Allow4011NoNo
16913315METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2020May 2023Allow3510NoNo
16913306METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2020May 2023Allow3410NoNo
16902368METHODS FOR PRODUCING HEPATOCYTESJune 2020March 2023Allow3310NoNo
16895732EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCERJune 2020July 2023Abandon3710NoNo
16890697PHARMACEUTICAL COMPOSITION COMPRISING AIMP2-DX2 FOR PREVENTING OR TREATING NEURONAL DISEASES AND USE THEREOFJune 2020June 2024Allow4930YesNo
16869394STEM CELL COMPOSITIONS FOR COSMETIC AND DERMATOLOGIC USEMay 2020May 2023Abandon3610NoNo
16869232METHODS AND PRODUCTS FOR TRANSFECTING CELLSMay 2020February 2021Allow1010YesNo
16857894METHODS AND PRODUCTS FOR TRANSFECTING CELLSApril 2020September 2020Allow510NoNo
16757811COMPOSITIONS AND METHODS USEFUL IN REGENERATIVE MEDICINEApril 2020August 2024Allow5261YesNo
16811086STEM CELL-DERIVED SERTOLI-LIKE CELL, PREPARATION METHOD THEREFOR, AND USE THEREOFMarch 2020June 2024Allow5141YesNo
16808170METHOD FOR PREPARATION OF RETINAL GANGLION CELLSMarch 2020February 2024Allow4840YesNo
16800988DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPYFebruary 2020December 2023Allow4520NoNo
16787980RECOMBINANT ADENO-ASSOCIATED VECTORS FOR TARGETED TREATMENTFebruary 2020July 2023Allow4111YesNo
16638440METHOD FOR DEVELOPING ORGAN THAT LACKS SPECIFIC FUNCTIONAL CELLFebruary 2020July 2021Allow1720YesNo
16776765METHODS AND PRODUCTS FOR TRANSFECTING CELLSJanuary 2020April 2020Allow210NoNo
16752535METHODS FOR REPROGRAMMING CELLS AND USES THEREOFJanuary 2020June 2023Allow4110NoNo
16752462METHODS FOR REPROGRAMMING CELLS AND USES THEREOFJanuary 2020May 2023Abandon4010NoNo
16747406METHODS FOR USE OF SEX SORTED SEMEN TO IMPROVE GENETIC MANAGEMENT IN SWINEJanuary 2020June 2024Allow5340NoNo
16737768METHODS FOR MAKING AND USING SINOATRIAL NODE-LIKE PACEMAKER CARDIOMYOCYTES AND VENTRICULAR-LIKE CARDIOMYOCYTESJanuary 2020March 2023Allow3910NoNo
16734892THIENOPYRIMIDINES AND USES THEREOFJanuary 2020April 2023Abandon3901NoNo
16626052IMMORTALIZED SWEAT GLAND MYOEPITHELIAL CELLDecember 2019May 2021Allow1711YesNo
16715597METHODS FOR COLLECTING AND USING PLACENTA CORD BLOOD STEM CELLSDecember 2019December 2023Abandon4820NoNo
16708007METHODS FOR INCREASING GENETIC PROGRESS IN A LINE OR BREED OF SWINE USING SEX-SELECTED SPERM CELLSDecember 2019January 2023Allow3710NoNo
16702275RECOMBINANT NK CELLS EXPRESSING CO-STIMULATORY MOLECULESDecember 2019March 2023Allow4011YesNo
16617241A THERAPY FOR POLYGLUTAMINE (POLYQ) DISEASESNovember 2019August 2022Allow3230YesNo
16614541METHODS OF INHIBITING AGING AND TREATING AGING-RELATED DISORDERSNovember 2019March 2024Abandon5231NoNo
16669094METHODS FOR ALTERING GENE EXPRESSION FOR GENETIC DISORDERSOctober 2019June 2024Abandon5531NoNo
16665821METHODS FOR REPROGRAMMING SOMATIC CELLSOctober 2019January 2024Allow5021NoNo
16609110GENETICALLY ENGINEERED NON-HUMAN MAMMAL, CONSTRUCTION METHOD THEREFOR AND USE THEREOFOctober 2019September 2023Allow4721YesNo
16659214LIVER-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOFOctober 2019January 2023Allow3811NoNo
16656484GENOMIC ENGINEERING OF PLURIPOTENT CELLSOctober 2019December 2021Allow2631YesNo
16605489METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCULAR DYSTROPHYOctober 2019February 2023Allow4011YesNo
16576411ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOFSeptember 2019November 2020Allow1411YesNo
16495677METHOD OF DETECTING POLYCOMB REPRESSIVE COMPLEX ACTIVITYSeptember 2019March 2024Allow5421YesNo
16567059METHODS AND PRODUCTS FOR TRANSFECTING CELLSSeptember 2019June 2022Allow3310NoNo
16567682NON-MEIOTIC ALLELE INTROGRESSIONSeptember 2019November 2020Allow1411YesNo
16567655NON-MEIOTIC ALLELE INTROGRESSIONSeptember 2019September 2020Allow1221YesNo
16562497METHODS AND PRODUCTS FOR TRANSFECTIONSeptember 2019June 2022Allow3410NoNo
16554792DECELLULARIZATION AND RECELLULARIZATION OF ORGANS AND TISSUESAugust 2019September 2022Abandon3742YesNo
16550475METHOD FOR THE TREATMENT OF MALIGNANCIESAugust 2019September 2022Allow3710NoNo
16541516CAPSIDAugust 2019July 2024Allow5942YesNo
16527629CARDIAC MYOFIBRIL INDUCTIONJuly 2019August 2022Abandon3601NoNo
16526327ADENO-ASSOCIATED VIRUS VECTORS ENCODING MODIFIED G6PC AND USES THEREOFJuly 2019August 2022Allow3711NoNo
16523567AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASEJuly 2019May 2023Allow4521NoNo
16519179Prevention and treatment of bone and cartilage damage or diseaseJuly 2019September 2022Allow3821YesNo
16460160DETARGETED ADENOVIRUS VARIANTS AND RELATED METHODSJuly 2019March 2022Allow3210YesNo
16454168MEDIA FOR CULTURING STEM CELLSJune 2019August 2022Allow3711NoNo
16452376PLURIPOTENT STEM CELL THAT INDUCES REPAIR AND REGENERATION AFTER MYOCARDIAL INFARCTIONJune 2019January 2020Allow710NoNo
16449438MICROFLUIDIC DEVICE, SYSTEM AND METHODS THEREOF FOR MEASURING AND RECORDING ELECTRICAL SIGNALS FROM A POOL OF MULTIPLE NEMATODESJune 2019May 2022Allow3501YesNo
16443418BOS TAURUS VARIETY 'JE840003146074527' AND METHODS OF USE THEROFJune 2019February 2021Allow2031YesNo
16435441GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD28June 2019December 2021Allow3041NoNo
16430251GENETICALLY STERILE ANIMALSJune 2019November 2022Abandon4221NoNo
16428763TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRSMay 2019February 2020Allow810YesNo
16426081Methods for monitoring physiological status of a body organMay 2019August 2022Allow3911NoNo
16424356NON-MEIOTIC ALLELE INTROGRESSIONMay 2019September 2020Allow1621YesNo
16424201MODIFIED NK-92 haNK003 CELLS FOR THE CLINICMay 2019May 2020Allow1211YesNo
16409656GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TIM-3May 2019September 2021Allow2831YesNo
16402175METHODS AND PRODUCTS FOR TRANSFECTING CELLSMay 2019September 2019Allow410NoNo
16379668GENOMIC ENGINEERING OF PLURIPOTENT CELLSApril 2019September 2020Allow1721YesNo
16374482METHODS AND PRODUCTS FOR TRANSFECTIONApril 2019August 2019Allow510NoNo
16365306BOS TAURUS Variety 'HO840003150607238' and Methods of Use ThereofMarch 2019February 2021Allow2332YesNo
16294619EFFICIENT NON-MEIOTIC ALLELE INTROGRESSION IN LIVESTOCKMarch 2019November 2021Abandon3340YesNo
16284443FLOWABLE BIRTH TISSUE COMPOSITION AND RELATED METHODSFebruary 2019February 2021Allow2321NoNo
16281490METHODS OF GENERATING GLIAL AND NEURONAL CELLS AND USE OF SAME FOR THE TREATMENT OF MEDICAL CONDITIONS OF THE CNSFebruary 2019June 2022Allow4011NoNo
16077682CULTURE MEDIUM FOR USE IN DIFFERENTIATION OF PLURIPOTENT STEM CELL INTO NEURAL STEM CELL, AND USE THEREOFJanuary 2019June 2021Abandon3420NoNo
16248569METHODS FOR INCREASING GENETIC PROGRESS IN A LINE OR BREED OF SWINE USING SEX-SELECTED SPERM CELLSJanuary 2019September 2019Allow810NoNo
16245435DECELLULARIZATION AND RECELLULARIZATION OF SOLID ORGANSJanuary 2019September 2023Abandon5621NoNo
16239315METHODS FOR USE OF SEX SORTED SEMEN TO IMPROVE GENETIC MANAGEMENT IN SWINEJanuary 2019September 2019Allow810NoNo
16082926CELL REPROGRAMMING METHOD USING PHYSICAL STIMULATION-MEDIATED ENVIRONMENTAL INFLUXDecember 2018October 2023Allow6051YesNo
16216903GENERATION AND MAINTENANCE OF STEM CELLSDecember 2018March 2024Allow6040YesNo
16209807TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRSDecember 2018May 2019Allow510NoNo
16206816EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCERNovember 2018January 2020Allow1410YesNo
16204320ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTSNovember 2018August 2022Allow4511YesNo
16201392Hybrid Dairy Cattle and Systems for Maximizing Hybrid AdvantageNovember 2018November 2022Abandon4711YesNo
16200974Methods And Compositions For Regulating Gene ExpressionNovember 2018August 2022Allow4410NoNo
16199715NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTIONNovember 2018September 2024Abandon6050YesNo
16195005METHODS FOR REPROGRAMMING CELLS AND USES THEREOFNovember 2018September 2019Allow1010NoNo
16189658Hybrid Dairy Cattle and Systems for Maximizing Hybrid AdvantageNovember 2018December 2021Allow3700NoNo
16189603Hybrid Dairy Cattle and Systems for Maximizing Hybrid AdvantageNovember 2018April 2022Allow4110NoNo
16184466AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASENovember 2018April 2019Allow510YesNo
16183144NON-HUMAN ANIMALS HAVING A MUTANT KYNURENINASE GENENovember 2018April 2022Abandon4110NoNo
16180835METHOD OF PREPARING INJECTION SOLUTIONNovember 2018July 2023Abandon5621NoNo
16180666Methods for monitoring physiological status of a body organNovember 2018May 2019Allow610NoNo
16175141LIVER-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOFOctober 2018June 2019Allow810NoNo
16165324TRANSFERRIN RECEPTOR TRANSGENIC MODELSOctober 2018September 2022Allow4720NoNo
16163334MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENTOctober 2018February 2023Allow5231NoNo
16094006METHODS AND COMPOSITIONS TO ENHANCE THE ANTI-INFLAMMATORY EFFECTS OF INTERLEUKIN 10October 2018June 2024Abandon6061YesNo
16159375REJUVENATED AGED HEMATOPOIETIC STEM CELLS AND METHODS OF USEOctober 2018February 2024Allow6051YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NOBLE, MARCIA STEPHENS.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
2
(50.0%)
Examiner Reversed
2
(50.0%)
Reversal Percentile
69.9%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
74
Allowed After Appeal Filing
13
(17.6%)
Not Allowed After Appeal Filing
61
(82.4%)
Filing Benefit Percentile
22.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NOBLE, MARCIA STEPHENS - Prosecution Strategy Guide

Executive Summary

Examiner NOBLE, MARCIA STEPHENS works in Art Unit 1632 and has examined 870 patent applications in our dataset. With an allowance rate of 60.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner NOBLE, MARCIA STEPHENS's allowance rate of 60.9% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NOBLE, MARCIA STEPHENS receive 2.23 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NOBLE, MARCIA STEPHENS is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +48.9% benefit to allowance rate for applications examined by NOBLE, MARCIA STEPHENS. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 43% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 90.5% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 84.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.0% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.4% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.